413 related articles for article (PubMed ID: 33208943)
1. Small-molecule-induced polymerization triggers degradation of BCL6.
Słabicki M; Yoon H; Koeppel J; Nitsch L; Roy Burman SS; Di Genua C; Donovan KA; Sperling AS; Hunkeler M; Tsai JM; Sharma R; Guirguis A; Zou C; Chudasama P; Gasser JA; Miller PG; Scholl C; Fröhling S; Nowak RP; Fischer ES; Ebert BL
Nature; 2020 Dec; 588(7836):164-168. PubMed ID: 33208943
[TBL] [Abstract][Full Text] [Related]
2. Chemically Induced Degradation of the Oncogenic Transcription Factor BCL6.
Kerres N; Steurer S; Schlager S; Bader G; Berger H; Caligiuri M; Dank C; Engen JR; Ettmayer P; Fischerauer B; Flotzinger G; Gerlach D; Gerstberger T; Gmaschitz T; Greb P; Han B; Heyes E; Iacob RE; Kessler D; Kölle H; Lamarre L; Lancia DR; Lucas S; Mayer M; Mayr K; Mischerikow N; Mück K; Peinsipp C; Petermann O; Reiser U; Rudolph D; Rumpel K; Salomon C; Scharn D; Schnitzer R; Schrenk A; Schweifer N; Thompson D; Traxler E; Varecka R; Voss T; Weiss-Puxbaum A; Winkler S; Zheng X; Zoephel A; Kraut N; McConnell D; Pearson M; Koegl M
Cell Rep; 2017 Sep; 20(12):2860-2875. PubMed ID: 28930682
[TBL] [Abstract][Full Text] [Related]
3. Development of a Novel B-Cell Lymphoma 6 (BCL6) PROTAC To Provide Insight into Small Molecule Targeting of BCL6.
McCoull W; Cheung T; Anderson E; Barton P; Burgess J; Byth K; Cao Q; Castaldi MP; Chen H; Chiarparin E; Carbajo RJ; Code E; Cowan S; Davey PR; Ferguson AD; Fillery S; Fuller NO; Gao N; Hargreaves D; Howard MR; Hu J; Kawatkar A; Kemmitt PD; Leo E; Molina DM; O'Connell N; Petteruti P; Rasmusson T; Raubo P; Rawlins PB; Ricchiuto P; Robb GR; Schenone M; Waring MJ; Zinda M; Fawell S; Wilson DM
ACS Chem Biol; 2018 Nov; 13(11):3131-3141. PubMed ID: 30335946
[TBL] [Abstract][Full Text] [Related]
4. Aryl Hydrocarbon Receptor Interacting Protein Maintains Germinal Center B Cells through Suppression of BCL6 Degradation.
Sun D; Stopka-Farooqui U; Barry S; Aksoy E; Parsonage G; Vossenkämper A; Capasso M; Wan X; Norris S; Marshall JL; Clear A; Gribben J; MacDonald TT; Buckley CD; Korbonits M; Haworth O
Cell Rep; 2019 Apr; 27(5):1461-1471.e4. PubMed ID: 31042473
[TBL] [Abstract][Full Text] [Related]
5. The E3 ubiquitin-ligase Bmi1/Ring1A controls the proteasomal degradation of Top2alpha cleavage complex - a potentially new drug target.
Alchanati I; Teicher C; Cohen G; Shemesh V; Barr HM; Nakache P; Ben-Avraham D; Idelevich A; Angel I; Livnah N; Tuvia S; Reiss Y; Taglicht D; Erez O
PLoS One; 2009 Dec; 4(12):e8104. PubMed ID: 19956605
[TBL] [Abstract][Full Text] [Related]
6. Covalent Ligand Screening Uncovers a RNF4 E3 Ligase Recruiter for Targeted Protein Degradation Applications.
Ward CC; Kleinman JI; Brittain SM; Lee PS; Chung CYS; Kim K; Petri Y; Thomas JR; Tallarico JA; McKenna JM; Schirle M; Nomura DK
ACS Chem Biol; 2019 Nov; 14(11):2430-2440. PubMed ID: 31059647
[TBL] [Abstract][Full Text] [Related]
7. An orally available small molecule BCL6 inhibitor effectively suppresses diffuse large B cell lymphoma cells growth in vitro and in vivo.
Xing Y; Guo W; Wu M; Xie J; Huang D; Hu P; Zhou M; Zhang L; Zhang Q; Wang P; Wang X; Wang G; Wu H; Zhou C; Chen Y; Liu M; Yi Z; Sun Z
Cancer Lett; 2022 Mar; 529():100-111. PubMed ID: 34990752
[TBL] [Abstract][Full Text] [Related]
8. Small molecule PROTACs in targeted therapy: An emerging strategy to induce protein degradation.
Xi M; Chen Y; Yang H; Xu H; Du K; Wu C; Xu Y; Deng L; Luo X; Yu L; Wu Y; Gao X; Cai T; Chen B; Shen R; Sun H
Eur J Med Chem; 2019 Jul; 174():159-180. PubMed ID: 31035238
[TBL] [Abstract][Full Text] [Related]
9. Gluing Proteins for Targeted Degradation.
Naito M; Murata S
Cancer Cell; 2021 Jan; 39(1):19-21. PubMed ID: 33434510
[TBL] [Abstract][Full Text] [Related]
10. Structural basis of Apt48 inhibition of the BCL6 BTB domain.
Zacharchenko T; Kalverda AP; Wright SC
Structure; 2022 Mar; 30(3):396-407.e3. PubMed ID: 34774129
[TBL] [Abstract][Full Text] [Related]
11. Targeted degradation via direct 26S proteasome recruitment.
Bashore C; Prakash S; Johnson MC; Conrad RJ; Kekessie IA; Scales SJ; Ishisoko N; Kleinheinz T; Liu PS; Popovych N; Wecksler AT; Zhou L; Tam C; Zilberleyb I; Srinivasan R; Blake RA; Song A; Staben ST; Zhang Y; Arnott D; Fairbrother WJ; Foster SA; Wertz IE; Ciferri C; Dueber EC
Nat Chem Biol; 2023 Jan; 19(1):55-63. PubMed ID: 36577875
[TBL] [Abstract][Full Text] [Related]
12. Cutting edge: T follicular helper cell differentiation is defective in the absence of Bcl6 BTB repressor domain function.
Nance JP; Bélanger S; Johnston RJ; Takemori T; Crotty S
J Immunol; 2015 Jun; 194(12):5599-603. PubMed ID: 25957170
[TBL] [Abstract][Full Text] [Related]
13. Stabilization of HIPK2 by escape from proteasomal degradation mediated by the E3 ubiquitin ligase Siah1.
Kim SY; Choi DW; Kim EA; Choi CY
Cancer Lett; 2009 Jul; 279(2):177-84. PubMed ID: 19250734
[TBL] [Abstract][Full Text] [Related]
14. Small molecule induced polymerization of BCL6 facilitates SIAH1 mediated degradation.
Rana S; Natarajan A
Signal Transduct Target Ther; 2021 Apr; 6(1):142. PubMed ID: 33795634
[No Abstract] [Full Text] [Related]
15. NAC1 attenuates BCL6 negative autoregulation and functions as a BCL6 coactivator of FOXQ1 transcription in cancer cells.
Gao M; Herlinger AL; Wu R; Wang TL; Shih IM; Kong B; Rangel LBA; Yang JM
Aging (Albany NY); 2020 May; 12(10):9275-9291. PubMed ID: 32412910
[TBL] [Abstract][Full Text] [Related]
16. Progress toward B-Cell Lymphoma 6 BTB Domain Inhibitors for the Treatment of Diffuse Large B-Cell Lymphoma and Beyond.
Ai Y; Hwang L; MacKerell AD; Melnick A; Xue F
J Med Chem; 2021 Apr; 64(8):4333-4358. PubMed ID: 33844535
[TBL] [Abstract][Full Text] [Related]
17. Targeted protein degradation and the enzymology of degraders.
Fisher SL; Phillips AJ
Curr Opin Chem Biol; 2018 Jun; 44():47-55. PubMed ID: 29885948
[TBL] [Abstract][Full Text] [Related]
18. Lessons in PROTAC Design from Selective Degradation with a Promiscuous Warhead.
Bondeson DP; Smith BE; Burslem GM; Buhimschi AD; Hines J; Jaime-Figueroa S; Wang J; Hamman BD; Ishchenko A; Crews CM
Cell Chem Biol; 2018 Jan; 25(1):78-87.e5. PubMed ID: 29129718
[TBL] [Abstract][Full Text] [Related]
19. Preclinical Studies of PROTACs in Hematological Malignancies.
Fuchs O; Bokorova R
Cardiovasc Hematol Disord Drug Targets; 2021; 21(1):7-22. PubMed ID: 33687890
[TBL] [Abstract][Full Text] [Related]
20. An essential EBV latent antigen 3C binds Bcl6 for targeted degradation and cell proliferation.
Pei Y; Banerjee S; Jha HC; Sun Z; Robertson ES
PLoS Pathog; 2017 Jul; 13(7):e1006500. PubMed ID: 28738086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
